🏭 Peptide CDMO Capacity Landscape
A comprehensive comparative analysis of global peptide CDMO synthesis capabilities, purification capacities, quality certifications (GMP/FDA/EU), facility distribution, and 2023–2028 capacity expansion plans. This report covers 15+ companies with detailed comparisons, technology capability matrices, and a selection decision framework.
1. Global Major Peptide CDMO Capacity Comparison
| CDMO Name |
Headquarters |
Solid-Phase Synthesis Scale |
Purification Capability |
Quality Certifications |
Core Bases |
2024–2027 Expansion Plans |
| Bachem (Switzerland) |
Basel |
50,000L (total reactor volume) |
Multi-column prep-HPLC, 10+ systems |
FDA, EU GMP, NMPA |
Bubendorf CH + Torrance USA |
Switzerland expansion +25,000L by 2026 |
| PolyPeptide (France) |
Paris |
35,000L (total volume) |
8 prep-HPLC systems |
FDA, EU GMP |
France+Sweden+USA |
French site expansion to 45,000L |
| WuXi AppTec (TIDES) |
Changzhou, China |
40,000L→60,000L(2025) |
20+ preparative HPLC systems |
NMPA, FDA, EU GMP |
Changzhou+Shanghai+Philadelphia, USA |
Changzhou Phase II: +20,000L |
| Sinomartek |
Deqing, China |
2,000 kg/yr→5,000 kg/yr(2025) |
12 purification lines |
NMPA, FDA DMF |
Deqing base |
New workshop Q4 2025 commissioning |
| Sainuo Biotech |
Chengdu/Zhangjiakou |
1,500 kg/yr |
8 purification lines |
NMPA, FDA DMF |
Chengdu+Zhangjiakou |
Zhangjiakou Phase II 2026 |
| Asymchem |
Tianjin |
10,000L |
6 prep-HPLC systems |
NMPA, FDA |
Tianjin+Shanghai |
Continuous flow line expansion |
| CordenPharma (Germany) |
Plheim |
15,000L |
Multi-column system |
FDA, EU GMP, JP |
Germany+USA |
Peptide line expansion underway |
| US Peptide CDMOs |
Multiple |
Distributed 1,000–5,000L |
Limited |
FDA |
Multiple US states |
Constrained by high costs |
| Jiuzhou Pharma |
Taizhou, China |
3,000L (peptide zone) |
5 prep-HPLC systems |
NMPA, FDA |
Taizhou+Beijing |
Extending peptide capacity |
| SENO Biotechnology |
Zhangjiakou |
R&D mg–kg + GMP grade |
Multiple prep-HPLC |
NMPA GMP |
Zhangjiakou |
Build-to-demand expansion |
| STA (Shanghai) |
Shanghai |
6,000L (peptide) |
8 prep-HPLC systems |
NMPA, FDA, EU |
Waigaoqiao, Shanghai |
Peptide capacity doubling 2025 |
| Pharmaron |
Beijing |
3,000L (peptide) |
4 prep-HPLC systems |
NMPA, FDA |
Beijing+Ningbo |
Peptide platform buildout 2025 |
| Aurisco |
Chengdu |
2,000 kg/yr |
6 purification lines |
NMPA, FDA |
Chengdu |
GLP-1 intermediate expansion |
| Hybio |
Shenzhen |
1,200 kg/yr |
5 prep-HPLC systems |
NMPA, FDA DMF |
Shenzhen+Wuhan |
Export-oriented expansion |
| Sunsom |
Haikou |
800 kg/yr |
4 purification lines |
NMPA |
Haikou |
Peptide generic API |
2. Technology Capability Matrix
| CDMO |
SPPS |
LPPS (Fragment) |
Enzymatic Synthesis |
Continuous Flow |
Hybrid |
Recombinant Expression |
Prep HPLC Purification |
Lyophilization |
| Bachem |
⭐⭐⭐⭐⭐ |
⭐⭐⭐⭐⭐ |
⭐⭐⭐⭐ |
⭐⭐⭐ |
⭐⭐⭐⭐⭐ |
⭐⭐⭐ |
⭐⭐⭐⭐⭐ |
⭐⭐⭐⭐⭐ |
| WuXi AppTec |
⭐⭐⭐⭐⭐ |
⭐⭐⭐⭐⭐ |
⭐⭐⭐⭐ |
⭐⭐⭐⭐ |
⭐⭐⭐⭐⭐ |
⭐⭐⭐ |
⭐⭐⭐⭐⭐ |
⭐⭐⭐⭐ |
| PolyPeptide |
⭐⭐⭐⭐⭐ |
⭐⭐⭐⭐ |
⭐⭐⭐ |
⭐⭐⭐ |
⭐⭐⭐⭐ |
⭐⭐ |
⭐⭐⭐⭐ |
⭐⭐⭐⭐ |
| Sinomartek |
⭐⭐⭐⭐ |
⭐⭐⭐ |
⭐⭐ |
⭐⭐ |
⭐⭐⭐ |
— |
⭐⭐⭐⭐ |
⭐⭐⭐ |
| Asymchem |
⭐⭐⭐⭐ |
⭐⭐⭐⭐ |
⭐⭐⭐ |
⭐⭐⭐⭐⭐ |
⭐⭐⭐⭐ |
— |
⭐⭐⭐⭐ |
⭐⭐⭐ |
| CordenPharma |
⭐⭐⭐⭐⭐ |
⭐⭐⭐⭐ |
⭐⭐⭐ |
⭐⭐⭐ |
⭐⭐⭐⭐ |
⭐⭐ |
⭐⭐⭐⭐ |
⭐⭐⭐⭐ |
| Sainuo Biotech |
⭐⭐⭐⭐ |
⭐⭐⭐ |
⭐⭐ |
⭐⭐ |
⭐⭐⭐ |
— |
⭐⭐⭐⭐ |
⭐⭐⭐ |
| Jiuzhou Pharma |
⭐⭐⭐ |
⭐⭐⭐ |
⭐⭐ |
⭐⭐ |
⭐⭐⭐ |
— |
⭐⭐⭐⭐ |
⭐⭐⭐ |
| SENO Biotechnology |
⭐⭐⭐⭐ |
⭐⭐⭐ |
⭐⭐ |
⭐⭐⭐ |
⭐⭐⭐ |
— |
⭐⭐⭐⭐ |
⭐⭐⭐ |
| STA |
⭐⭐⭐⭐ |
⭐⭐⭐⭐ |
⭐⭐⭐ |
⭐⭐⭐ |
⭐⭐⭐⭐ |
— |
⭐⭐⭐⭐ |
⭐⭐⭐⭐ |
3. Synthesis Capability Breakdown (by Weight Scale)
| Scale Level |
Capable CDMOs |
Typical Client Need |
Representative Project Type |
| mg–100g (R&D) |
Nearly all CDMOs |
Early discovery, PK/PD studies |
Lead optimization, tox samples |
| 100g–5kg (Pilot) |
WuXi, Bachem, Sinomartek, Sainuo |
Tox/Phase I clinical |
Clinical sample GMP production |
| 5kg–50kg (Commercial) |
WuXi, Bachem, PolyPeptide, Sinomartek |
Phase III / early commercial |
Semaglutide API bulk production |
| 50kg–200kg+ (Large scale) |
Bachem, WuXi (post-expansion), Sinomartek (post-expansion) |
Commercial scale-up |
GLP-1 generic API stockpiling |
GLP-1 Capacity Bottleneck Remains the Biggest Challenge
Global GLP-1 API (Semaglutide + Tirzepatide) demand was approximately 12,000 kg in 2024, with capacity utilization already exceeding 90%. With 2025–2027 demand projected to reach 25,000–35,000 kg/yr as generics receive approval, even fully executing current expansion plans may leave a 10–20% capacity gap.
4. CDMO Selection Decision Framework
| Decision Factor |
Early R&D (mg scale) |
Clinical Phase (100g–5kg) |
Commercial (>5kg) |
| Technical Capability |
35% ⭐⭐⭐⭐⭐ |
25% |
15% |
| Cost Control |
20% |
20% |
35% ⭐⭐⭐⭐⭐ |
| Delivery Speed |
20% |
30% ⭐⭐⭐⭐ |
15% |
| Regulatory Compliance |
5% |
15% |
25% ⭐⭐⭐⭐ |
| IP Protection |
15% |
10% |
10% |
| Track Record |
5% |
— |
— |
| Total |
100% |
100% |
100% |
| Key Selection Questions |
Early R&D Recommendation |
Clinical/Commercial Recommendation |
| Which CDMOs have experience with the same sequence? |
Prioritize Bachem/WuXi |
Same priority |
| Minimum order quantity (MOQ)? |
Choose flexible options (Sainuo/SENO) |
Focus on scale (Sinomartek/WuXi) |
| Does it support FDA DMF filing? |
Preferential requirement |
Must meet |
| Does purification capability meet purity requirements? |
Accept >95% |
Must be >99.0% |
| Cost weight? |
Not primary factor |
Core factor |
5. Capacity Expansion Timeline (2023–2028)
| Company |
2023 |
2024 |
2025 |
2026 |
2027 |
2028 (Planned) |
| Bachem |
50,000L (baseline) |
— |
Phase II start |
+25,000L→75,000L |
— |
Phase III planning |
| WuXi AppTec |
30,000L |
40,000L |
60,000L (+20,000L) |
— |
Phase III planning |
Potential 80,000L |
| Sinomartek |
1,200 kg/yr |
2,000 kg/yr |
5,000 kg/yr |
— |
7,000 kg/yr (planned) |
10,000 kg/yr |
| PolyPeptide |
32,000L |
35,000L |
— |
45,000L |
— |
— |
| Asymchem |
6,000L |
8,000L |
10,000L (+continuous) |
12,000L |
— |
— |
| Sainuo Biotech |
1,200 kg/yr |
1,500 kg/yr |
— |
Zhangjiakou Phase II |
2,500 kg/yr |
— |
| STA |
3,000L |
4,500L |
6,000L |
8,000L |
— |
— |
| SENO Biotechnology |
R&D scale |
R&D + small GMP |
GMP expansion |
Build-to-demand |
Build-to-demand |
Build-to-demand |
6. Quality Certification Coverage Matrix
| CDMO |
cGMP (NMPA) |
FDA DMF/PAI |
EU GMP |
Japan PMDA |
Other Certifications |
| Bachem |
✅ |
✅ |
✅ |
✅ |
🇨🇭 Swissmedic |
| PolyPeptide |
✅ |
✅ |
✅ |
✅ |
🇫🇷 ANSM |
| WuXi AppTec |
✅ |
✅ |
✅ |
✅ |
🇨🇳 NMPA Grade A |
| Sinomartek |
✅ |
✅ 2024 approved |
In process |
— |
— |
| Sainuo Biotech |
✅ |
✅ |
Partial |
— |
— |
| Asymchem |
✅ |
✅ |
✅ |
Partial |
— |
| CordenPharma |
— |
✅ |
✅ |
✅ |
🇩🇪 DE |
| Jiuzhou Pharma |
✅ |
Yes |
— |
— |
— |
| SENO Biotechnology |
✅ |
In process |
— |
— |
— |
7. Purification Capability Comparison
| CDMO |
Purification Technology |
Max Single Batch |
Typical Purity Target |
Specialty Technology |
| Bachem |
Preparative RP-HPLC + SFC |
10 kg/batch |
≥99.5% |
Multi-column continuous chromatography |
| WuXi AppTec |
RP-HPLC + Ion exchange + SFC |
15 kg/batch |
99.0–99.8% |
Digital twin purification simulation |
| Sinomartek |
RP-HPLC |
5 kg/batch |
≥99.0% |
Cost-optimized process |
| Sainuo Biotech |
RP-HPLC + Size exclusion |
3 kg/batch |
≥98.5% |
Impurity removal expertise |
| PolyPeptide |
Multi-set prep-HPLC |
8 kg/batch |
≥99.0% |
GMP-grade purification |
| Asymchem |
RP-HPLC + Ion exchange |
6 kg/batch |
≥99.0% |
Continuous elution technology |
8. China CDMO vs. EU/US CDMO Comparison
| Comparison Dimension |
🇨🇳 China CDMO |
🇪🇺/🇺🇸 EU/US CDMO |
| Labor Cost |
Low (China engineer $30–60K/yr) |
High (EU/US engineer $100–200K/yr) |
| Synthesis Cost |
Low-medium ($50–200/g GMP API) |
High ($200–800/g GMP API) |
| Technology Leadership |
Rapidly catching up in continuous flow/enzymatic |
Full SPPS/LPPS process maturity |
| Quality System |
Rapidly improving; top players passed FDA PAI |
Long-term FDA/EU GMP compliance |
| IP Protection |
Continuously improving, stronger contractual terms |
Highly mature, robust legal framework |
| Delivery Speed |
Fast (China supply chain efficiency) |
Moderate (more management layers) |
| Flexibility |
High (quick project change response) |
Medium (more rigid processes) |
| Client Trust |
Building steadily (GLP-1 validated) |
Long-standing trust relationships |
| Capacity Scale |
Rapidly growing (WuXi 60,000L planned) |
Steady expansion |
| Language/Communication |
Bilingual Chinese/English teams |
Primarily English |
9. CDMO Client Collaboration Models
| Collaboration Model |
Applicable Client Type |
Contract Structure |
Typical Cycle |
Client Advantage |
CDMO Advantage |
| Fee-for-Service (FFS) |
Early R&D / Biotech |
Milestone-based phased payments |
3–12 months |
Flexible termination, phased investment |
Stable cash flow |
| Long-Term Supply Agreement (LTA) |
Commercial-stage pharma |
Locked pricing + annual volume commitment |
2–5 years |
Price stability, supply assurance |
High capacity utilization |
| Strategic Partnership |
Large multinational pharma |
Exclusive multi-project collaboration |
3–10 years |
Priority capacity + technology sharing |
Long-term revenue, co-development |
| Technology License |
Innovative Biotech |
Upfront + milestones + sales royalty |
5–10 years |
Low upfront investment |
High return potential |
| Joint Development (JDA) |
Technology-complementary companies |
Cost-sharing + benefit-sharing |
2–5 years |
Risk sharing, accelerated development |
Access to new technology |
| Virtual Client |
Asset-light Biotech |
End-to-end full outsourcing |
Continuous |
No need for in-house capacity |
High client stickiness |
🏭 CDMO Collaboration Consultation: SENO Biotechnology, based in Zhangjiakou City, Hebei Province, operates NMPA GMP-certified peptide production workshops equipped with multiple preparative HPLC systems and complete purification/lyophilization post-processing capabilities. We provide end-to-end services from mg-level process development to kg-level GMP peptide API production, supporting domestic and international client audits. View SENO Biotechnology's peptide CDMO service details → Visit senopeptide.com/services/